Home > Cloud PRWire > Genetoo Presented Photonics-Texturing Of Prosthetic Implants At CLEO 2022

Genetoo Presented Photonics-Texturing Of Prosthetic Implants At CLEO 2022

Genetoo’s appearance at the conference affirms its position as a leading proponent of innovative biotechnology for the medical sector. The announcement details how the company is changing the face of bacteria elimination on implant surfaces. Recent data published by the company reveals that Genetoo’s photonics technology eradicates 99.998% of S. Aureus MRSA bacteria upon contact.

More details can be found at https://Genetoo.com

The company’s latest launch offers medical providers state-of-the-art laser texturing that inhibits bacteria attachments and biofilm growth, allowing the interaction of body tissue around the implant site. Genetoo provides a viable, environmentally-friendly alternative to standard antibiotic treatments for implant patients.

The CLEO conference is a highly-respected and globally acclaimed showcase for leading research in fields such as biophotonics, manufacturing, and telecommunications. Held in San Jose, CA, this yearly event puts a spotlight on companies such as Genetoo that are impacting the application of laser technology in the medical world.

Genetoo’s technology modifies surface energy via direct laser ablative surface patterning. This reduces bacterial adhesion and inhibits the formation and growth of biofouling. The company’s proprietary technology creates surfaces with bactericidal properties. Studies suggest this process is unrivaled in terms of its effectiveness against bacterial growth on prosthetics.

Genetoo’s laser surface texturing can be used in a variety of medical contexts. These include orthopedic, dental, cardiac, and electronic implants as well as endoscopic devices. Genetoo’s investment in research and development is increasing its productivity and reducing operational costs over the long term.

About Genetoo

The company has been leading the way in biotechnical research innovation in the US since 2017. Genetoo’s core technology has been licensed by the National Aeronautics and Space Administration. An active partnership with the NASA Space Technology Mission Directorate and its keynote presentation at the CLEO conference is indicative of Genetoo’s position at the forefront of the biomedical laser processing space.

A spokesperson says, “Our goal is to reduce the number of infections associated with prosthetic implant surgeries, cutting all of the related pain and collateral costs.”

Genetoo continues to establish its reputation as a pioneer of laser surface texturing, arming the medical community and implant patients with safer, more precise, cost-effective bacteria elimination solutions.

For more information, please visit https://Genetoo.com

Genetoo Inc.
chris@genetoo.com
+1-202-495-1991
9841 Washingtonian Blvd
#200
United States

comtex tracking

COMTEX_408380983/2764/2022-06-08T09:02:07

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Sahyadri Times journalist was involved in the writing and production of this article.